{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.7","upperLimit":"71.5","value":"56.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"Percentage of participants with a best overall confirmed CR or PR as assessed per RANO criteria by central independent assessment. The 95% CIs were computed using two-sided exact binomial method. CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses. PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically. This analysis was conducted at the end of the trial (after the primary endpoint analysis cut-off date) and includes a longer follow-up time","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the HGG cohort received dabrafenib (orally, twice daily and dosed based on weight and age) and trametinib (orally, once daily in combination with the first daily dose of dabrafenib and dosed based on weight)","id":"OG000","title":"HGG Cohort: Dabrafenib and Trametinib"}],"paramType":"NUMBER","populationDescription":"All participants on the HGG cohort to whom study treatment had been assigned and who received at least one dose of study treatment","reportingStatus":"POSTED","timeFrame":"Up to approx 4.8 years","title":"HGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using RANO Criteria (Longer Follow-up Time)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Percentage of participants"}